Post on 02-Jun-2018
8/11/2019 Lecture 3 Principles of Controlled Drug Delivery
http://slidepdf.com/reader/full/lecture-3-principles-of-controlled-drug-delivery 1/12
Lecture 3: PRINCIPLES of CONTROLLED DRUG DELIVERY
• Controlled Drug Delivery versus Sustained Release
o Controlled Drug Delivery Active agent combined with other components to produce delivery
system DDS are usually macroscopic
Involve combinations of active agents with inert polymeric materials
ust include a component that can be engineered to regulate an
essential characteristic such as duration of release! rate of release ortargeting
ust have a duration of action longer than one day
o Sustained Release
Achieved by mi"ing active agent with e"cipients to alter agent#s rate
of dissolution in $I tract or adsorption from local in%ection site &ssentially achieved by drug formulation
• 'iocompatibility
o (illiam#s definition: ability of a material to perform with an appropriate host
response in a specific applicationo odified definitions
Long)term implanted devices: ability of the device to perform intended
functions with a desired degree of incorporation in the host! withouteliciting any undesirable local or systemic effects in that host
Short)term implantable devices: ability to carry out its intended
function with flowing blood! with minimum interaction between thedevice and blood that adversely affects device performance andwithout inducing uncontrolled activation of cellular plasma proteincascades
*issue &ngineering +roducts: biocompatibility of a scaffold or matri"
refers to the ability of the device to perform as a substrate that willsupport appropriate cellular activity! including facilitation of molecular and mechanical signaling systems to optimi,e tissue regeneration!
without eliciting any undesirable effects in those cells or any local orsystemic responses in the eventual host
• 'iocompatible 'iomaterials
o 'iomaterials divided into - ma%or classes
POLYMERS - will be focused on
etals
8/11/2019 Lecture 3 Principles of Controlled Drug Delivery
http://slidepdf.com/reader/full/lecture-3-principles-of-controlled-drug-delivery 2/12
Ceramics .including carbons! glass ceramics! glasses/
0atural materials .both plants and animals/
o +olymers
olecular weight
In polymer synthesis! polymer is produced with a distribution ofmolecular weights
Linear polymers used in biomedical applications generally have a
number average molecular weight in the range of 12! to4! and weight average molecular weight from 2! to3!
Increasing molecular weight corresponds to increasing physical
properties *acticity
Arrangement of substituents around the e"tended polymer chain
Isotactic 5 chains located on the same side of ,ig),ag chain
Syndiotactic 5 chains have substituents alternating from side to
side Atactic 5 substituents appear at random on either side of chain
Crystallinity
+olymers either amorphous or semicrystalline! never completely
crystalline *endency of polymer to crystalli,e enhanced by small side groups
and chain regularity echanical properties
6ltimate mechanical properties of polymers at large deformations
important in selecting polymers for biomedical applications 6ltimate strength 5 stress at or near failure
7atigue behavior 5 how a polymer withstands cycles of stress and
release *hermal properties
*g 5 temperature at which all long)range segmental polymeric
motion ceases 8aries from polymer to polymer
+olymers used below *g tend to be hard and glassy and below
*g tend to be rubbery
*g always below *m
*arget region for biomedical applications is rubbery plateau region
above *g where long)range segmental motion is occurring butthermal energy is insufficient to overcome entanglementinteractions that inhibit flow
Crystalline polymers tend to be tough and ductile
8/11/2019 Lecture 3 Principles of Controlled Drug Delivery
http://slidepdf.com/reader/full/lecture-3-principles-of-controlled-drug-delivery 3/12
Chemically cross)lin9ed polymers e"hibit modulus versus
temperature behavior analogous to that of linear amorphous polymers! until flow regime is approached
•Controlled Release Delivery Systems
I Diffusion Controlled Systems
• Reservoir Systems
Diffusion through planar membranes
o Drug release from reservoir into e"ternal solution in three steps
Dissolution of drug in polymer
Diffusion of drug across polymer membrane
Dissolution of drug into e"ternal phase
o Assumptions
0o bul9 flow .no convection/
0o generation;consumption of drug
Drug is dilute within material
Drug release is controlled by thic9ness and composition of
surrounding membrane Diffusion through cylindrical membranes
o Drug must dissolve in polymer before diffusing through
cylinder wallo C4 .from e<uation in lecture slides/ most generally e<uals the
solubility of drug in the polymer if the drug concentration inthe polymer is very high
Commercially available reservoir systems
o =cusert>
System delivers pilocarpine! a drug that reduces pressure in
the eye! used to treat glaucoma +laced in lower eye lid
Administered medicine for one wee9
(as not successful due to patient compliance 5 patients felt
more comfortable using the regular drops that placing aforeign ob%ect in eye? and pricing 5 device was five timesmore e"pensive than regular drops
8/11/2019 Lecture 3 Principles of Controlled Drug Delivery
http://slidepdf.com/reader/full/lecture-3-principles-of-controlled-drug-delivery 4/12
o 0orplant>
Consists of @ silicone rods with 3@mg of levonorgestreldissolved in polymer matri"
Implanted under s9in in upper arm
Delivers progestin .hormone/ continuously for up to five
years Discontinued due to multiple lawsuits in the 6SA
o *ransdermal Systems
0orplant> implants and subse<uentinsertion
$lobal sales among *DD products
8/11/2019 Lecture 3 Principles of Controlled Drug Delivery
http://slidepdf.com/reader/full/lecture-3-principles-of-controlled-drug-delivery 5/12
*ransdermal patches are the primary transdermal
technology approved by the 7DA 7DA has approved! in 11 years! 32 patch products!
spanning 43 molecules ar9et approached 41 billion in 14 in the 6S
alone! based on 44 molecules .12 billion in 6S!&uropean mar9ets! and Bapan/
&nables steady blood)level profile! thus reducing side
effects and sometimes improved efficacy
ost common technology is drug)in)adhesive .shown inthe figure below/
Active systems .iontophoresis! electroporation!
sonophoresis! magnetophoresis/ and microneedle systems.3#s *S! mentioned previously/ are also beinginvestigated for delivery of peptides and macromolecules
Successful Systems
&straderm> .estradiol/ 5 Al,a
0icoDerm> C> .nicotine/ ) Al,a
Duragesic> .fentanyl/ 5 Al,a
*estoderm> .testosterone/ 5 Al,a
Classification of *ransdermal Drug Delivery Devices
All mar9eted with Al,a#sD)*RA0S> technology 5 clear patch with up to1mg per day of drug
8/11/2019 Lecture 3 Principles of Controlled Drug Delivery
http://slidepdf.com/reader/full/lecture-3-principles-of-controlled-drug-delivery 6/12
*ransderm)0itro> .nitroglycerine/) Al,a
*ulobuterol .Asthma patch! Bapan/
A8&8A
$el matri" adhesive technology produces minimal
irritation to the stratum corneum =versaturation of adhesive polymer with
medication induces partial drug crystalli,ationwhich translates into higher drug concentrations in patch
Asthma patch .tulobuterol/ in Bapan is an approved
patch
A8&8A#s gel matri" adhesivetechnology with crystal reservoir
technology
8/11/2019 Lecture 3 Principles of Controlled Drug Delivery
http://slidepdf.com/reader/full/lecture-3-principles-of-controlled-drug-delivery 7/12
• atri" Systems
6seful for release of proteins
Drug molecules dissolved or disperse throughout a solid polymer
phase with homogeneous dispersion aterials utili,ed are biodegradable polymers which slowly dissolve
Rate of polymer degradation;dissolution controls the rate of drug
delivery igh surface area)to)volume ratio increases release rate by allowing
direct access to the matri" e"terior to more particles Rate of release decreases with time since drug molecules near matri"
surface are released first A model slab has a cumulative release proportional to t∴release
rate decreases with t
o If matri" is formed as a hemisphere! ,ero)order 9inetics can be
obtainedo Longer diffusion distance for molecules on outside of
hemisphere balanced by increase in surface area +seudo)state appro"imation
o Drugs loaded as fine solid particles∴drug concentration
within matri" higher than drug solubility in a<ueous solutiono 'oundary between dissolved and dispersed drug is present
which moves from outer surface of matri" to the center asrelease proceeds
o *his implies linear concentration gradient from solid;dissolved
drug interface to releasing surfaceo Re<uires that total concentration is much higher than drug
solubility Commerciali,ed Systems
o Salvona ) DermaSal>
1= soluble patch
Ingredients dissolved in a polymer matri"
atri" disintegrates after adhesion! yet utili,es no
adhesives
Cross)section ofDermaSal>
patch
8/11/2019 Lecture 3 Principles of Controlled Drug Delivery
http://slidepdf.com/reader/full/lecture-3-principles-of-controlled-drug-delivery 8/12
o 8alera 5 ydron Implant *echnology
8antas> ) long duration LR therapy for advanced
prostate cancer .Indevas +harmaceuticals/ ydron 5 hydrogel polymers spun into small tubes 4E long
and 4;FE diameter Contains micropores for drug diffusion
0onbiodegradable
4)year continuous! near ,ero)order release rates
II Swelling Controlled Systems
• Incorporation of drug within a hydrophilic polymer that swells when in an
a<ueous environment
• Drug molecules cannot diffuse out of device without water molecules
diffusing in
• Devices have a semi)permeable membrane that allows water movement
into device but prevents salt and drug from diffusing out
• Drug molecules diffuse out due to the pressure increase brought on by the
volumetric increase of the device
• &"ample of an elementary osmotic pump ) =R=S> .Al,a/
8antas> implant .8alera/
=R=S> ) best for water)soluble compounds
8/11/2019 Lecture 3 Principles of Controlled Drug Delivery
http://slidepdf.com/reader/full/lecture-3-principles-of-controlled-drug-delivery 9/12
Drugs mar9eted with this device
o +rocardia GL>
After incorporation of =R=S> technology! drug#s use
e"panded to treatment of angina and hypertension
o Concerta> ) once)a)day treatment of Attention Deficityperactivity Disorder .ADD/
o Ditropan GL> ) once)a)day treatment of overactive bladder
• &"ample of osmotic driven system ) Duros> Implant *echnology
*itanium alloy cylinder
0on)biodegradable
8iadur> .leuprolide/) once)a)year implant for treatment of advanced
prostate cancer
=R=S> =ral Delivery *echnology 8ariations
Duros> Implant *echnology
8/11/2019 Lecture 3 Principles of Controlled Drug Delivery
http://slidepdf.com/reader/full/lecture-3-principles-of-controlled-drug-delivery 10/12
III 'iodegradable Systems
• Advantage ) Supporting matri" will dissolve after drug release∴no
residual material remains in tissue
• Disadvantage 5 release of large <uantities of potentially harmful polymer
degradation products into body
• aterials should
Degrade in a controllable fashion
Degrade into naturally occurring or inert chemicals
• 'ioerosion 5 physical process of dissolution of a polymer matri" or
microsphere! in which a solid material slowly losses mass and eventuallydisappears =ccurs once constituent polymer molecules become sufficiently small
and then dissolve *wo ideali,ed patterns of erosion
o 'ul9 erosion
+olymer disappears uniformly throught the material
icroporous matri" becomes spongy! with water)filled
holes becoming larger until matri" is no longermechanically stable
o
Surface erosion +olymer disappears from the surface! so matri" becomes
progressively smaller with time +referred since drug release from slowly shrin9ing matri"
could be more predictable +otentially provides constant rate of polymer erosion
• 'iodegradation 5 decrease in ( of polymer within matri" after
placement within biological environment 'iologicals ) en,ymes
ydrolytic brea9down 5 1= degradation
• ost commonly used polymers
poly.lactic acid/ ! poly.glycolic acid/ and copolymers
o p$A 5 simplest! aliphatic! linear polyester
o pLa 5 hydrophobic
o +roperties controlled by ( and copolymeri,ation
o Different copolymers degrade at varying rates
o 0o linear relationship between ratio of glycolic acid to lactic
acid and physicomechanical properties of the corresponding
8/11/2019 Lecture 3 Principles of Controlled Drug Delivery
http://slidepdf.com/reader/full/lecture-3-principles-of-controlled-drug-delivery 11/12
copolymers .eg! 2:2 copolymers degrade more rapidly thaneither p$A or pLA/
poly.anhydride/
o Contain the most hydrolytically unstable polymer lin9age
o Degrade by surface erosion without need to incorporate
e"cipients into device formulationo *o control degradation! hydrophobic polymers can be
polymeri,ed via anhydride lin9ages to prevent or control water penetration into matri" 5 rate of degradation is ad%usted
Aliphatic poly.anhydrides/ degrade within days
Aromatic poly.anhydrides/ degrade over several years
+ossess e"cellent in vivo biocompatibility
poly.ortho esters/
o Al,amer> ) 4Hs by Al,a Corporation
o Degradation produces a diol and a lactone! which is converted
to J)hydro"ybutyric acid +rocess is autocatalytic
o A compound such as sodium bicarbonate must be incorporated
into polymeric matri" to prevent abrupt degradation anderosion
I8 Liposomes
• *erm introduced by 'angham et al to describe one or more concentric
lipid bilayers incorporating an e<ual number of a<ueous compartments
• 7orm spontaneously in a<ueous media
• Si,e and shape can be varied by changing mi"ture of phospholipids!
degree of saturation of the fatty acid side chains! and conditions offormation
• ydrophobic drugs may be loaded into liposome membranes while
hydrophilic drugs can be loaded into a<ueous core regions
• Disappear rapidly in blood
t4;1 may be increased by coupling to water)soluble polymers .eg!
+&$/
'ul9 erosion
Surface erosion
8/11/2019 Lecture 3 Principles of Controlled Drug Delivery
http://slidepdf.com/reader/full/lecture-3-principles-of-controlled-drug-delivery 12/12
• Commercially available liposome systems
Al,a 5 Stealth> Liposomal *echnology
o 7or I8 drug delivery
o Incorporate +&$ coating
o 'asis for Do"il> .do"orubicin Cl liposome suspension/
anticancer agent
Amphotericin '
o Amphocil
o Am'iosome 5 liposomal amphotericin '
o A'LC 5 Amphotericin ' lipid comple"
Amphotericin ' comple"ed with dimiristoyl
phosphatidylcholine and dimiristoyl phosphatidylglycerol Lesser concentrations of drug achieved in blood but higher
in liver! spleen! and lungs Renal concentration similar
Reduced to"icity and increased action! allowing for
administration of higher dosages
alf)life of various anticancer agents